Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-19 (Cancelled)

20. (Previously Presented) A pharmaceutical composition comprising IgY that originates from an egg of a bird hyperimmunised with Enterobacter cloacae.

21. (Previously Presented) The pharmaceutical composition according to claim 20, wherein the pharmaceutical composition is formulated as a freeze dried or lyophilised powder, a solution, an emulsion, a lozenge, a tablet or as a capsule together with any other pharmaceutically acceptable carrier or diluent.

22. (Previously Presented) The pharmaceutical composition according to claim 21, wherein the pharmaceutical further comprises a buffering agent.

23. (Previously Presented) The pharmaceutical composition according to claim 21, further comprising a nutritional agent.

24. (Currently Amended) The pharmaceutical composition according to claim 22~~ or 23~~, wherein the nutritional agent or buffering agent is human breast milk or a substitute therefore.

25. (Previously Presented) A method of prophylaxis or treatment of enteric infections in newborn infants, prematurely born infants, infants having an immature immune system, patients suffering from temporary immunodeficiency and immunodeficiency diseases such as AIDS, comprising the step of:

-administrating to said infant or patient a pharmaceutical composition comprising IgY that originates from an egg of a bird hyperimmunised with a microbe.

26. (Previously Presented) The method according to claim 25, wherein the infection is a bacterial infection.

27. (Previously Presented) The method according to claim 25, wherein the microbe is a bacterium, virus, fungus or parasite.

28. (Previously Presented) The method according to claim 25, wherein the microbe is Enterobacter cloacae.

29. (Previously Presented) The method according to claim 25, further comprising formulating the pharmaceutical composition as a freeze dried or lyophilised powder, a solution, an emulsion, a lozenge, a tablet or as a capsule or administering it together with any other pharmaceutically acceptable carrier or diluent.

30. (Previously Presented) The method according to claim 25, wherein the pharmaceutical composition is administered together with a nutritional agent.

31. (Previously Presented) The method according to claim 30, wherein the nutritional agent is human breast milk or a substitute therefore.

32. (Previously Presented) The method according to claim 25, wherein the pharmaceutical composition is administered together with a buffering agent.

33. (Previously Presented) The method according to claim 32, wherein the buffering agent is human breast milk or a substitute therefore.

34. (Previously Presented) The method according to claim 25, wherein the pharmaceutical composition is administered to newborn infants having an immature immune system.

35. (Previously Presented) The method according to claim 25, wherein the pharmaceutical composition is administered to newborn infants having a weight below 2500g.

36. (Previously Presented) The method according to claim 25, wherein the pharmaceutical composition is administered to prematurely born infants.

37. (Previously Presented) The method according to claim 25, wherein the pharmaceutical composition is

administered to newborn infants having a pH above 1,5 in their stomach.

38. (Previously Presented) The method according to claim 25, wherein the pharmaceutical composition is administered to newborn infants having pH between 1,5 and 4 in their stomach.

39. (New) The pharmaceutical composition according to claim 23, wherein the nutritional agent or buffering agent is human breast milk or a substitute therefore.